<?xml version="1.0" encoding="UTF-8"?>
<p id="par0095">This replicon system was then used in high-throughput screening for specific anti-RSV drugs acting on the replication machinery of this virus. The small-molecule compound AZ-27 was found to inhibit transcription and replication initiation 
 <xref rid="bib0395" ref-type="bibr">[79]</xref>. This finding was later confirmed using the minigenome system 
 <xref rid="bib0400" ref-type="bibr">[80]</xref>. In 2014, Laganas 
 <italic>et al</italic>. further screened the Astra Zeneca compound library in a high-throughput approach using the RSV replicon and identified three new lead compounds – nucleoside analogues and non-nucleoside inhibitors of the RSV RdRp 
 <xref rid="bib0405" ref-type="bibr">[81]</xref>. In 2015 &gt; 100 nucleoside analogue polymerase inhibitors were screened using the HeLa395-RV replicon cell line. Compound ALS-8176 was found to be a first-in-class small-molecule inhibitor of RSV replication, acting by chain termination during replication 
 <xref rid="bib0410" ref-type="bibr">[82]</xref>. The compound was abandoned by Johnson &amp; Johnson in March 2019 after Phase IIb trials 
 <xref rid="bib0415" ref-type="bibr">[83]</xref>.
</p>
